Investigational Drug Information for Brilacidin
✉ Email this page to a colleague
What is the drug development status for Brilacidin?
Brilacidin is an investigational drug.
There have been 4 clinical trials for Brilacidin.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2014.
The most common disease conditions in clinical trials are Skin Diseases, Infectious, Infections, and COVID-19. The leading clinical trial sponsors are Innovation Pharmaceuticals, Inc., Cellceutix Corporation, and [disabled in preview].
There are thirty US patents protecting this investigational drug and four hundred and sixty-eight international patents.
Summary for Brilacidin
US Patents | 30 |
International Patents | 468 |
US Patent Applications | 96 |
WIPO Patent Applications | 70 |
Japanese Patent Applications | 8 |
Clinical Trial Progress | Phase 2 (2014-02-01) |
Vendors | 12 |
Recent Clinical Trials for Brilacidin
Title | Sponsor | Phase |
---|---|---|
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 | Innovation Pharmaceuticals, Inc. | Phase 2 |
A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers | Innovation Pharmaceuticals, Inc. | Phase 1 |
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer | Cellceutix Corporation | Phase 2 |
Clinical Trial Summary for Brilacidin
Top disease conditions for Brilacidin
Top clinical trial sponsors for Brilacidin
US Patents for Brilacidin
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Brilacidin | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
Brilacidin | See Plans and Pricing | Bis-cyclic guanidines as antibacterial agents | UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) | See Plans and Pricing |
Brilacidin | See Plans and Pricing | Arylamide compounds and compositions and uses thereof | Innovation Pharmaceuticals Inc. (Beverly, MA) | See Plans and Pricing |
Brilacidin | See Plans and Pricing | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof | Redwood Bioscience, Inc. (Emeryville, CA) | See Plans and Pricing |
Brilacidin | See Plans and Pricing | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. Scherer Technologies, LLC (Carson City, NV) | See Plans and Pricing |
Brilacidin | See Plans and Pricing | Compounds and methods of treating infections | NEOCULI PTY LTD (Victoria, AU) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Brilacidin
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Brilacidin | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
Brilacidin | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
Brilacidin | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
Brilacidin | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
Brilacidin | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
Brilacidin | Japan | JP2019520866 | 2036-05-05 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |